Cargando…

Neuroprotective Therapy in Parkinson's Disease: Current Status and New Directions from Experimental and Genetic Clues

Despite successful treatment of Parkinson's disease (PD) with a wide variety of symptomatic therapy, the disease continues to progress and drug-resistance symptoms become the predominant factors producing the disability of PD patients. Neuroprotective therapies have been tested, but clinically...

Descripción completa

Detalles Bibliográficos
Autores principales: Lin, William, Kang, Un Jung
Formato: Texto
Lenguaje:English
Publicado: Korean Neurological Association 2005
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2854916/
https://www.ncbi.nlm.nih.gov/pubmed/20396458
http://dx.doi.org/10.3988/jcn.2005.1.2.107
_version_ 1782180137340502016
author Lin, William
Kang, Un Jung
author_facet Lin, William
Kang, Un Jung
author_sort Lin, William
collection PubMed
description Despite successful treatment of Parkinson's disease (PD) with a wide variety of symptomatic therapy, the disease continues to progress and drug-resistance symptoms become the predominant factors producing the disability of PD patients. Neuroprotective therapies have been tested, but clinically effective drugs have not been found yet. New insights gained from studies of genetic forms of PD point to the common pathogenic mechanisms that have been suspected in sporadic forms of the disease and may provide new approaches for the future neuroprotective therapies.
format Text
id pubmed-2854916
institution National Center for Biotechnology Information
language English
publishDate 2005
publisher Korean Neurological Association
record_format MEDLINE/PubMed
spelling pubmed-28549162010-04-15 Neuroprotective Therapy in Parkinson's Disease: Current Status and New Directions from Experimental and Genetic Clues Lin, William Kang, Un Jung J Clin Neurol Review Despite successful treatment of Parkinson's disease (PD) with a wide variety of symptomatic therapy, the disease continues to progress and drug-resistance symptoms become the predominant factors producing the disability of PD patients. Neuroprotective therapies have been tested, but clinically effective drugs have not been found yet. New insights gained from studies of genetic forms of PD point to the common pathogenic mechanisms that have been suspected in sporadic forms of the disease and may provide new approaches for the future neuroprotective therapies. Korean Neurological Association 2005-10 2005-10-20 /pmc/articles/PMC2854916/ /pubmed/20396458 http://dx.doi.org/10.3988/jcn.2005.1.2.107 Text en Copyright © 2005 Korean Neurological Association
spellingShingle Review
Lin, William
Kang, Un Jung
Neuroprotective Therapy in Parkinson's Disease: Current Status and New Directions from Experimental and Genetic Clues
title Neuroprotective Therapy in Parkinson's Disease: Current Status and New Directions from Experimental and Genetic Clues
title_full Neuroprotective Therapy in Parkinson's Disease: Current Status and New Directions from Experimental and Genetic Clues
title_fullStr Neuroprotective Therapy in Parkinson's Disease: Current Status and New Directions from Experimental and Genetic Clues
title_full_unstemmed Neuroprotective Therapy in Parkinson's Disease: Current Status and New Directions from Experimental and Genetic Clues
title_short Neuroprotective Therapy in Parkinson's Disease: Current Status and New Directions from Experimental and Genetic Clues
title_sort neuroprotective therapy in parkinson's disease: current status and new directions from experimental and genetic clues
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2854916/
https://www.ncbi.nlm.nih.gov/pubmed/20396458
http://dx.doi.org/10.3988/jcn.2005.1.2.107
work_keys_str_mv AT linwilliam neuroprotectivetherapyinparkinsonsdiseasecurrentstatusandnewdirectionsfromexperimentalandgeneticclues
AT kangunjung neuroprotectivetherapyinparkinsonsdiseasecurrentstatusandnewdirectionsfromexperimentalandgeneticclues